sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed Form 8.3 under the Irish Takeover Panel Act, 1997. This disclosure identifies Vanguard's interests in Avadel Pharmaceuticals plc. The significant date noted is 29 October 2025. Vanguard controls 5,518,512 ordinary shares, representing a 5.67% stake. This document marks an opening position disclosure regarding Avadel Pharmaceuticals’ shares.
Vanguard executed limited trading activities, purchasing 285 shares and selling 6,955, both transactions priced at $18.90 per share. No additional financial instrument dealings, such as derivatives, were reported. The disclosure indicates no indemnity or other dealing agreements, nor are there attachments in the form of Supplemental Form 8.
Overall, this disclosure aligns with Rule 8.3 mandates, focusing on significant shareholders in target companies during takeover periods.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.